A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer
Latest Information Update: 21 Jun 2024
At a glance
- Drugs Ipatasertib (Primary) ; Abiraterone; Abiraterone acetate; Prednisolone; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms IPATential150
- Sponsors Chugai Pharmaceutical; Roche
- 22 May 2024 Status changed from active, no longer recruiting to completed.
- 09 May 2024 This trial has been completed in Germany (Global end date: 24 Apr 2024).
- 07 May 2024 This trial has been completed in Belgium, according to European Clinical Trials Database record.